On 31 January 2014, members of Navamedic Management have exercised 50 000 options into shares. The options were part of the Company's Stock Option Plan and the shares will be legally issued and fully paid for.

Per-Anders Elvertrø, Chief Scientific Officer and head of Pharma Commercialization has exercised 30 000 stock options at a price of NOK 9.50. Number of shares held once the transaction has effectively been completed are 30 000.

Bjørn Lindholt, CFO of Navamedic ASA has exercised 20 000 stock options at a price of NOK 11. At once this transaction has effectively been completed, Lindholt and close associates will hold a total of 88,000 shares in Navamedic ASA.

Navamedic ASA is a Norwegian pharmaceutical products company, marketing and distributing more than 100 products in the Nordic and Benelux markets. The Company operates three business areas; Pharma Products, Medical Nutrition and Consumer Care based on its relationship with a number of pharmaceutical product manufacturers.

For further information, please contact:

CFO Bjørn Lindholt, Navamedic ASA

E-mail:bjorn [dot] lindholt [at] navamedic [dot] com
Mobile: +47 93006601

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act

distributed by